The effects of pazopanib on doxorubicin pharmacokinetics in children and adults with non-rhabdomyosarcoma soft tissue sarcoma: a report from Children’s Oncology Group and NRG Oncology study ARST1321-Reference-Cited by-同舟云学术

The effects of pazopanib on doxorubicin pharmacokinetics in children and adults with non-rhabdomyosarcoma soft tissue sarcoma: a report from Children’s Oncology Group and NRG Oncology study ARST1321

Published:2022-01-27 Issue:4 Volume:89 Page:551-557
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Gartrell J.^ORCID,Panetta J. C.,Baker S. D.,Chen Y. L.,Hawkins D. S.,Ostrenga A.,Scharschmidt T. J.,Spunt S. L.,Wang D.,Weiss A. R.

Funder

National Cancer Institute

St. Baldrick's Foundation

Seattle Children's Foundation

Kat's Crew Guild, Sarcoma Research Fund

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s00280-022-04397-4.pdf

Reference26 articles.

1. Waxweiler TV et al (2015) Non-rhabdomyosarcoma soft tissue sarcomas in children: a surveillance, epidemiology, and end results analysis validating COG risk stratifications. Int J Radiat Oncol Biol Phys 92(2):339–348

2. Spunt SL et al (2020) A risk-based treatment strategy for non-rhabdomyosarcoma soft-tissue sarcomas in patients younger than 30 years (ARST0332): a Children’s Oncology Group prospective study. Lancet Oncol 21(1):145–161

3. Hurwitz HI et al (2009) Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res 15(12):4220–4227

4. Glade Bender JL et al (2013) Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children’s oncology group phase I consortium report. J Clin Oncol 31(24):3034–3043

5. van der Graaf WT et al (2012) Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379(9829):1879–1886

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Children's Oncology Group's 2023 blueprint for research: Pharmacy;Pediatric Blood & Cancer;2023-07-17

2. Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas;European Journal of Cancer;2022-09

3. The treatment approach to pediatric non-rhabdomyosarcoma soft tissue sarcomas: a critical review from the INternational Soft Tissue SaRcoma ConsorTium;European Journal of Cancer;2022-07